Trial Profile
A Phase 3 Long-term Study of TAK-085 in Subjects With Hypertriglyceridemia
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Omega-3-acid ethyl esters (Primary) ; Ethyl eicosapentaenoic acid
- Indications Hypertriglyceridaemia
- Focus Adverse reactions; Registrational
- Sponsors Takeda
- 04 Sep 2013 Results presented at the ESC Congress 2013: Annual Congress of the European Society of Cardiology.
- 23 Aug 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 14 May 2011 New trial record